GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

2013). By offering these capabilities, POLYVIEW-3D plays a pivotal role in the optimization of mRNA-LNP vaccines. Its ability to model complex interactions at the molecular level, visualize the ...

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.

SINGAPORE – With a better understanding of their aspirations and encouraged by more polytechnic graduates winning places at the local universities, more O-level school leavers are choosing the ...

This is a guide for anyone who wants to turbo-charge their Fortnite level without glitching or doing anything you’d need to hide from the Fortnite police. Fortnite Chapter 6 Season 1 has ...

But scientists at Moderna are in the late stages of testing what could be the first such shot, using mRNA technology against the virus. Here’s what to know about norovirus and where things stand ...

The company’s latest RSV vaccine is yet to show promising sales. This has weighed on MRNA stock, down 52% since early 2024. Even if we look at a slightly longer period, the changes in MRNA stock ...

Wall Street is off to a volatile start in 2025, with investors stepping on the sell pedal after last week's jobs data, followed by a sharp about-face in sentiment following Wednesday's consumer ...

Nanohybrid complex (oAd/APP) in combination with DC (oAd/APP+DC) induced superior expression level of antitumor cytokines (IL-12, GM-CSF, and interferon gamma) than either oAd/APP or DC monotherapy in ...